What HHS published
The notice is Federal Register document 2026-22192 (docket HHS-OASH-2026-0496). It is an enforcement-discretion policy: HHS says it will not take action against a licensed 503A pharmacy that compounds one of six peptides for a named patient, when the pharmacy meets ten conditions. That is different from FDA approval, and none of the six is an FDA-approved drug. HHS opened a public comment period and can revise the policy.
HHS wrote it to give patients a more controlled alternative to research-use-only peptides from foreign manufacturers. LegitScript, which certifies online pharmacies and telehealth practices, began honoring the policy on November 2, 2026.
The six peptides and the form HHS allows for each
| Peptide | Form and route HHS allows | Next step |
|---|---|---|
| BPC-157 | BPC-157 acetate, by injection (under the skin or into muscle), by mouth, or on the skin | See the BPC-157 plan |
| TB-500 | TB-500 acetate, by injection (under the skin or into muscle) | See the TB-500 plan |
| MOTS-c | MOTS-c acetate, by injection (under the skin or into muscle) | See the MOTS-c plan |
| Epitalon | Epitalon acetate, by injection (under the skin or into muscle), dispensed in courses | See the Epitalon plan |
| Semax | Semax, as a nasal spray only | See the Semax nasal spray plan |
| KPV | KPV acetate, on the skin or by mouth only | Ask a physician at a free visit |
The ten conditions, and what you can check
Each condition is a rule for the pharmacy. Most of them leave something you can see on your label or ask for.
- The peptide is one of the six HHS listed. What you can check: The name on your label is one of the six.
- It matches the identity and route HHS set for it (the table above). What you can check: The label names the form and how you take it.
- The ingredient comes from an FDA-registered source, with a certificate of analysis that meets HHS’s testing table and is graded for human drug compounding. What you can check: Ask the pharmacy for the certificate of analysis for your lot.
- The original manufacturer is FDA-registered, follows current good manufacturing practice, and its site is named on the certificate. What you can check: The manufacturer’s site appears on that certificate.
- Serious side effects and quality problems are reported to FDA’s MedWatch program and to the states. What you can check: Your label tells you how to report a problem.
- The label reads “This is a compounded drug product. Not for resale.” What you can check: That line is on your vial or spray.
- One active ingredient per product. What you can check: Your prescription names one peptide.
- An oral form needs documented human absorption data for that formulation. What you can check: Applies only to capsules or other oral forms.
- The only device allowed is an FDA 510(k)-cleared syringe. What you can check: Your syringes come with the prescription.
- Every other federal drug rule still applies, including a prescription written for you by name. What you can check: Your name and your prescriber are on the label.
How the six got here
- April 15, 2026: FDA removed twelve peptides, these six among them, from Category 2 of its 503A bulk substance lists after their nominations were withdrawn.
- July 23–24, 2026: FDA’s Pharmacy Compounding Advisory Committee voted to recommend all six for the 503A Bulks List. The vote is advisory.
- October 30, 2026: HHS published the enforcement-discretion policy for the six.
- November 2, 2026: LegitScript began honoring the policy in its certification program.
Getting one prescribed at PepScribe
At PepScribe, a physician (MD) prescribes BPC-157, TB-500, MOTS-c, Epitalon and Semax nasal spray. You start with a free online visit: a short medical intake about your goals and history. The physician reviews it, most within 24 hours, and decides whether the peptide fits you and at what dose. You pay only if it is prescribed.
If it is, a licensed 503A pharmacy in the USA fills the single-ingredient peptide with your name on the label. No hidden overseas supply chain. Compounded peptides are not FDA-approved drugs, and no specific outcome is promised.
Frequently asked questions
Is BPC-157 legal now?
Since October 30, 2026, a licensed 503A pharmacy may compound single-ingredient BPC-157 acetate for a patient with a prescription, under HHS’s ten conditions. BPC-157 is still not an FDA-approved drug and is not on FDA’s 503A Bulks List.
Does the policy mean these peptides are FDA-approved?
No. The policy is enforcement discretion: HHS says it will not act against pharmacies that meet the conditions. FDA has not approved any of the six as a drug, and HHS can revise the policy.
Does the policy cover research peptides sold online?
The policy covers licensed 503A pharmacies compounding for a named patient with a prescription. HHS described it as a more controlled alternative to research-use-only peptides from foreign manufacturers.
Which form of KPV does the policy cover?
KPV acetate on the skin or by mouth. HHS did not list an injectable form of KPV.
Who prescribes at PepScribe?
For BPC-157, TB-500, MOTS-c, Epitalon and Semax nasal spray, a physician (MD) reviews your history and decides whether the peptide fits you. The online visit is free, and you pay only if it is prescribed.



